SCHEMBL748712

SCHEMBL748712

Cn1c(=O)oc2cc(Cl)c(Br)cc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.41
TSHR P16473 2/20 0.41
KMO O15229 2/20 0.41
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
LRRK2 Q5S007 1/20 0.38
JAK2 O60674 1/20 0.37
BTK Q06187 1/20 0.37
USP2 O75604 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16362387 0.81 ALDH1A1 (0.41) PKMTSHRKMOKDM4EPOLB
SCHEMBL30881275 0.81 ALDH1A1 (0.41) PKMTSHRKMOKDM4EPOLB
SCHEMBL782441 0.79 MEN1 (0.41) PKMTSHRKDM4EPOLBALDH1A1
SCHEMBL31180321 0.79 MEN1 (0.41) PKMTSHRKDM4EPOLBALDH1A1
SCHEMBL16362024 0.78 MAPK1 (0.40) PKMTSHRKDM4EPOLBALDH1A1
SCHEMBL16361867 0.77 ALDH1A1 (0.41) PKMTSHRKDM4EPOLBALDH1A1
SCHEMBL30881287 0.77 HTT (0.44) PKMTSHRKMOKDM4EALDH1A1
SCHEMBL30881273 0.77 MAPK1 (0.39) PKMTSHRKMOKDM4EPOLB
SCHEMBL1115715 0.76 PKM (0.41) PKMTSHRKMOKDM4EPOLB
SCHEMBL22323771 0.76 ALDH1A1 (0.43) PKMTSHRKDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024222814-A1 CYP11B2 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2024-10-31 WO disclosed
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 EP disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 US disclosed
EP-2430018-A2 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS Novartis AG (CH) 2012-03-21 EP disclosed
WO-2010130773-A2 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B2, CYP11B1, CYP21A2 PKM 814/4885TSHR 2587/4885KMO 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.